Targeting natural killer cell reactivity by employing antibody to NKp46: implications for type 1 diabetes.
Yossef R, Gur C, Shemesh A, Guttman O, Hadad U, Nedvetzki S, Miletić A, Nalbandyan K, Cerwenka A, Jonjic S, Mandelboim O, Porgador A.
Yossef R, et al. Among authors: miletic a.
PLoS One. 2015 Feb 26;10(2):e0118936. doi: 10.1371/journal.pone.0118936. eCollection 2015.
PLoS One. 2015.
PMID: 25719382
Free PMC article.